Race Commences Phase 1b/2 AML Trial at Chaim Sheba Israel
22 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed…
Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.
ASX Announcements
Share Price
Latest News
MST Access Investor Conference Presentation
Race Oncology’s Mr Phil Lynch (CEO & MD) and Dr Daniel Tillett (CSO & ED)…
Race Executes Key Contract for Israel Phase 2 AML Trial
Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the…
CEO Phil Lynch Talks to the Australian Shareholder Association Podcast
Race CEO/MD Phillip Lynch speaks to the Australia Shareholders Association about Race Oncology and our…
Race Executes Contract to Commence Phase 2 Extramedullary AML Trial
Contract Research Organisation Parexel has been appointed to support an Australian trial of Bisantrene in…
Race appoints Professor Michael Kelso as Principal Scientist
20 May 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of…
